SCHEMBL31727424

SCHEMBL31727424

COc1ccc(CN(C)c2ccc([N+](=O)[O-])nc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.50
▸ CRHBP P24387 1/20 0.44
▸ CRHR2 Q13324 1/20 0.44
▸ NPC1 O15118 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ LMNA P02545 2/20 0.41
▸ NR1D1 P20393 1/20 0.40
▸ NR1H3 Q13133 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PARP1 P09874 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ APLNR P35414 1/20 0.38
▸ SLC2A1 P11166 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2791587 0.76 MAPT (0.39) MAPTRAB9APOLBSMN1; SMN2
SCHEMBL30773532 0.75 MAPT (0.63) MAPTNPC1KMT2ARAB9AALDH1A1
SCHEMBL28384656 0.75 MAPT (0.63) MAPTNPC1KMT2ARAB9AALDH1A1
SCHEMBL19302284 0.75 PYCR1 (0.53) MAPTKMT2AALDH1A1LMNAPARP1
SCHEMBL6741043 0.74 MAPT (0.49) MAPTNPC1KMT2ARAB9AALDH1A1
SCHEMBL10265072 0.74 MAPT (0.42) MAPTNPC1KMT2ARAB9AALDH1A1
SCHEMBL4525335 0.72 ALDH1A1 (0.49) MAPTRAB9AALDH1A1POLBHTT
SCHEMBL1099100 0.72 RAB9A (0.45) MAPTNPC1KMT2ARAB9AALDH1A1
SCHEMBL21640132 0.72 MAPT (0.36) MAPTRAB9AALDH1A1LMNAPOLB
SCHEMBL2144585 0.71 CYP19A1 (0.47) MAPTCRHBPCRHR2NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025235363-A1 CYCLIN-DEPENDENT KINASE 4 DEGRADERS BLUEPRINT MEDICINES CORPORATION (US) 2025-11-13 — — WO disclosed
Send feedback